Nestlé To Develop Immunotherapies For Food Allergies
Biopharmaceutical company Enterome has signed a strategic R&D collaboration and license agreement with Nestlé Health Science targeting food allergies and inflammatory bowel disease (IBD).

Nestlé, Enterome Collaboration
Enterome is a clinical stage biopharmaceutical company developing immunomodulatory drugs based on its bacterial Mimicry drug discovery platform. As part of the agreement, Enterome will receive €40 million upfront in cash and equity from Nestlé Health Science. It will also be eligible to receive clinical and sales milestone payments for each licensed therapeutic candidate plus royalties on net sales. Enterome will be responsible for leading drug discovery activities and bear related costs up to the investigational new drug (IND) application.
Related news
Food allergy labels should be expanded, study suggests
Of the 2,999 cases analysed, 413 cases were linked to…
Read more >Food industry investment boom possible: nearly 200 billion forints in support decided
The first decisions have been made on supporting larger-scale developments…
Read more >Eight out of ten parents would like to buy everything in one place for the start of school – Pepco offers a solution for this
As the school year approaches, parents are once again faced…
Read more >More new products
Danone lines up yogurt facility expansion amid “explosive growth” in US
The Activia brand owner has made a “multi-million dollar investment”…
Read more >Denmark plans to scrap taxes on coffee, confectionery
The complete removal of taxes on coffee and confectionery is…
Read more >Katalin Neubauer: margin stop and mall stop do not serve the interests of retail
The government has extended the margin cap and tightened the…
Read more >